An open multicenter phase II trial of docetaxel–gemcitabine in Charlson score and performance status (PS) selected elderly patients with stage IIIB pleura/IV non-small-cell lung cancer (NSCLC): The GFPC 02-02a study

This publication has 35 references indexed in Scilit:

• Gemcitabine (GEM) and Vindesine (VDS) in advanced non-small cell lung cancer (NSCLC): A phase II study in elderly or poor performance status patients
  Lung Cancer, 2006
• Chemotherapy of advanced non-small cell lung cancer in elderly patients
  Annals of Oncology, 2006
• A phase II study of carboplatin and paclitaxel as first line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC)
  Lung Cancer, 2006
• Should Elderly Non–Small-Cell Lung Cancer Patients Be Offered Elderly-Specific Trials? Results of a Pooled Analysis From the North Central Cancer Treatment Group
  Journal of Clinical Oncology, 2005
• First line chemotherapy with gemcitabine in advanced non-small cell lung cancer elderly patients: a randomized phase II study of 3-week versus 4-week schedule
  Lung Cancer, 2005
• Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non-small cell lung cancer
  Seminars in Oncology, 2001
• New Guidelines to Evaluate the Response to Treatment in Solid Tumors
  JNCI Journal of the National Cancer Institute, 2000
• Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the lung cancer symptom scale
  Cancer, 1994
• Measuring the quality of life of cancer patients
  Journal of Chronic Diseases, 1981
• The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent
  Journal of Chronic Diseases, 1961